De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule.
DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0500, USA.
G V
GV
De Lucca
P K
PK
Jadhav
R E
RE
Waltermire
B J
BJ
Aungst
S
S
Erickson-Viitanen
P Y
PY
Lam
D000818:Animals; D001381:Azepines / Q000138:chemical synthesis; D001665:Binding Sites; D015195:Drug Design; D016333:HIV Protease / Q000737:chemistry; D017320:HIV Protease Inhibitors / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D006801:Humans; D008968:Molecular Conformation; D014508:Urea / Q000031:analogs & derivatives / Q000138:chemical synthesis
D001381:Azepines; D017320:HIV Protease Inhibitors; D014508:Urea; D016333:HIV Protease; C085816:DMP 323; C099851:DMP 450